Phase II Randomized, Placebo-Controlled Trial of PROSTVAC® (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Trial Profile

Phase II Randomized, Placebo-Controlled Trial of PROSTVAC® (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Rilimogene galvacirepvec (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 24 Jul 2015 According to Bavarian Nordic media release, first patient has been enrolled in this trial.
    • 05 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top